What the FDA labels say about taking them together
Buspirone and fluvoxamine
Fluvoxamine's FDA label of June 27, 2026 names buspirone in its warnings and precautions section; buspirone's label does not name fluvoxamine itself but warns about its class (serotonin reuptake inhibitors). The fluvoxamine label: “The risk is increased with concomitant use of other serotonergic drugs and with drugs that impair metabolism of serotonin, i.e., MAOIs.”
Check it at the source: the buspirone FDA label on DailyMed (effective December 22, 2023, Unichem Pharmaceuticals (USA), Inc.); the fluvoxamine FDA label on DailyMed (effective June 27, 2026, Zydus Pharmaceuticals USA Inc.).
What does the buspirone label say about fluvoxamine?
Buspirone's label does not name fluvoxamine itself; it warns about its class (serotonin reuptake inhibitors):
Buspirone label, warningsSerotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs, SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs such as linezolid and intravenous methylene blue), or with antipsychotics or other dopamine antagonists.
Source: FDA drug label (Buspirone Hydrochloride), Unichem Pharmaceuticals (USA), Inc., effective December 22, 2023 (SPL set a6bdf140-075e-445e-a62d-633a4b97f3a8), via openFDA; the full label on DailyMed
What does the fluvoxamine label say about buspirone?
Fluvoxamine label, warnings and precautionsThe development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including fluvoxamine maleate extended-release capsules, alone but particularly with concomitant use of serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
Fluvoxamine Maleate label (ANI Pharmaceuticals, Inc., August 4, 2025), drug interactionsOther Serotonergic Drugs: The concomitant use of serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort) with Fluvoxamine Maleate Tablets increases the risk of serotonin syndrome.
Fluvoxamine Maleate label (ANI Pharmaceuticals, Inc., August 4, 2025), warnings and precautionsThe risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications ( 4 ), Drug Interactions ( 7.1 )].
Source: FDA drug label (Fluvoxamine Maleate, NDA021519), ANI Pharmaceuticals, Inc., effective August 4, 2025 (SPL set 7ecd83ec-88f5-4f85-9cc2-9068375d8820), via openFDA
Source: FDA drug label (Fluvoxamine maleate extended-release), Zydus Pharmaceuticals USA Inc., effective June 27, 2026 (SPL set 6c71d4f6-54b5-4d3a-8d2f-b7773c92c32e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Buspirone | Fluvoxamine | |
|---|---|---|
| Labeled for | Anxiety | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.043 per tablet 15 mg tablet | $4.08 per capsule 100 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once